Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from ...
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiativ...
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical d...
Canaccord Genuity analyst Kyle Mikson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.
Request for insurance coverage aims to enhance early detection and treatment of esophageal precancer to prevent highly lethal e...
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0...
